This study, a national, multicenter, observational, ambispective, non-interventional study, will be conducted in French hospitals prescribing pomalidomide and already participating in the ongoing Imnovid registry.

This study will add to the registry. Indeed, pomalidomide-prescribing physicians and pharmacists dispensing pomalidomide have to enter into the Imnovid registry all patients who have been prescribed this drug since the date on which it was marketed regardless of the initiation date of pomalidomide or the indication for which it was prescribed.

Inclusion Criteria:

• Adult patient (age ≥ 18 yrs),
• Diagnosed with multiple myeloma (measurable or not),
• In whom pomalidomide treatment was first initiated between October 1, 2014, and September 30, 2019,
• Patient already included in the Imnovid registry,
• Having received oral and written information about the study, and having given their consent to participate.

Exclusion Criteria:

• Previous participation in a clinical trial with pomalidomide,
• Treatment with pomalidomide in a previous line,
• Simultaneous participation in a clinical trial.

The MIROIR study focuses on multiple myeloma patients treated with pomalidomide in France whose treatment was initiated between October 1, 2014, and September 30, 2019. Patients having initiated pomalidomide outside of this period or having received pomalidomide in a previous treatment line will not be included.